Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 4, 2026
- Edwards Lifesciences reported Q3 2026 sales of $1.72 billion, up 10.5%, and raised full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97 to $3.05.
- 10-Q report · filed Nov 4, 2026
- Edwards Lifesciences Corp reported first nine months of 2026 net sales of $5,105.1 million, up 13.5%, while a $220.2 million impairment and 31.2% effective tax rate contributed to lower diluted earnings per share.
The audio replay and transcript follow the call.